Original Research

Published on 02 Feb 2023

Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study

in Vaccines and Molecular Therapeutics

Sarra Mestiri
Maysaloun Merhi
Varghese P. Inchakalody
Nassiba Taib
Maria K. Smatti
Fareed Ahmad
Afsheen Raza
Fatma H. Ali
Shereena Hydrose
Queenie Fernandes

Frontiers in Immunology

doi 10.3389/fimmu.2023.1061255

3,411 views

Original Research

Published on 02 Feb 2023

Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis

in Vaccines and Molecular Therapeutics

Liu Bo
Liu Tianming
Fan Fengliang
Liang Wenping
Han Jinzuo
Xue Dongbo
Ma Biao
Sun Haijun

Frontiers in Immunology

doi 10.3389/fimmu.2023.1063548

2,713 views
1 citation

Original Research

Published on 02 Feb 2023

Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients

in Vaccines and Molecular Therapeutics

Isabel Pérez-Flores
Ignacio Juarez
Arianne S. Aiffil Meneses
Ana Lopez-Gomez
Natividad Calvo Romero
Beatriz Rodriguez-Cubillo
María Angeles Moreno de la Higuera
Belen Peix-Jiménez
Raquel Gonzalez-Garcia
Elvira Baos-Muñoz

Frontiers in Immunology

doi 10.3389/fimmu.2023.1111569

3,002 views
5 citations

Brief Research Report

Published on 31 Jan 2023

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus

in Vaccines and Molecular Therapeutics

Almohanad A. Alkayyal
Reham Ajina
Marco Cacciabue
Aaesha A. Alkayyal
Nizar H. Saeedi
Taofik Hussain Alshehry
Feras Kaboha
Mohammed A. Alotaibi
Nada Zaidan
Khalid Shah

Frontiers in Immunology

doi 10.3389/fimmu.2023.1082191

4,172 views
1 citation

Original Research

Published on 31 Jan 2023

A novel, non-neuronal acetylcholinesterase of schistosome parasites is essential for definitive host infection

in Vaccines and Molecular Therapeutics

Patrick J. Skelly
Akram A. Da’dara

Frontiers in Immunology

doi 10.3389/fimmu.2023.1056469

2,530 views
5 citations

Review

Published on 31 Jan 2023

Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19

in Vaccines and Molecular Therapeutics

Jingli Du
Yue Su
Ruilan Wang
Enjun Dong
Yan Cao
Wenjuan Zhao
Wenping Gong

Frontiers in Immunology

doi 10.3389/fimmu.2023.1118378

7,577 views
4 citations

Original Research

Published on 30 Jan 2023

Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines

in Vaccines and Molecular Therapeutics

Shaojun Liu
Joseph G. S. Tsun
Genevieve P. G. Fung
Grace C. Y. Lui
Kathy Y. Y. Chan
Paul K. S. Chan
Renee W. Y. Chan

Frontiers in Immunology

doi 10.3389/fimmu.2023.1127401

2,987 views
6 citations

Original Research

Published on 30 Jan 2023

Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature

in Vaccines and Molecular Therapeutics

Janneke W. Duijster
Thomas Lieber
Silvia Pacelli
Leontine Van Balveren
Loes S. Ruijs
Monika Raethke
Agnes Kant
Florence Van Hunsel

Frontiers in Immunology

doi 10.3389/fimmu.2023.1078736

7,091 views
25 citations

Original Research

Published on 27 Jan 2023

Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB

in Vaccines and Molecular Therapeutics

Peng Cheng
Fan Jiang
Guiyuan Wang
Jie Wang
Yong Xue
Liang Wang
Wenping Gong

Frontiers in Immunology

doi 10.3389/fimmu.2023.1102578

5,572 views
20 citations

Original Research

Published on 27 Jan 2023

Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern

in Vaccines and Molecular Therapeutics

Steven Y. Gao
Nancy B. Amaro-Mugridge
Jocelyn Madrid-Weiss
Nikolina Petkovic
Natasha Vanegas
Kumar Visvanathan
Bryan R. G. Williams
Jennifer A. MacDiarmid
Himanshu Brahmbhatt

Frontiers in Immunology

doi 10.3389/fimmu.2022.1038562

4,730 views
2 citations

Original Research

Published on 27 Jan 2023

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

in Vaccines and Molecular Therapeutics

Maria Rescigno
Chiara Agrati
Carlo Salvarani
Diana Giannarelli
Massimo Costantini
Alberto Mantovani
Raffaella Massafra
Pier Luigi Zinzani
Aldo Morrone
Stefania Notari

Frontiers in Immunology

doi 10.3389/fimmu.2023.1104124

4,453 views
12 citations

Original Research

Published on 26 Jan 2023

Immunoinformatics design of multivalent epitope vaccine against monkeypox virus and its variants using membrane-bound, enveloped, and extracellular proteins as targets

in Vaccines and Molecular Therapeutics

Muhammad Waqas
Shahkaar Aziz
Pietro Liò
Yumna Khan
Amjad Ali
Aqib Iqbal
Faizullah Khan
Fahad Nasser Almajhdi

Frontiers in Immunology

doi 10.3389/fimmu.2023.1091941

7,158 views
18 citations

Original Research

Published on 26 Jan 2023

Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination

in Vaccines and Molecular Therapeutics

Francisco J. Cimas
Javier Torres
Jesús Ontañón
Carlos de Cabo
Julia Lozano
María Ángeles Requena
Joaquín Blas
José Luis Rodríguez-García
Antonio Mas
Javier Solera

Frontiers in Immunology

doi 10.3389/fimmu.2023.1097747

2,816 views
2 citations

Correction

Published on 26 Jan 2023

Corrigendum: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

in Vaccines and Molecular Therapeutics

Shimeng Bai
Tianhan Yang
Cuisong Zhu
Meiqi Feng
Li Zhang
Ziling Zhang
Xiang Wang
Rui Yu
Xinghao Pan
Chen Zhao

Frontiers in Immunology

doi 10.3389/fimmu.2023.1146466

1,555 views

Original Research

Published on 26 Jan 2023

Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system

in Vaccines and Molecular Therapeutics

Jorge Armero-Gimenez
Ruud Wilbers
Arjen Schots
Charles Williams
Ricarda Finnern

Frontiers in Immunology

doi 10.3389/fimmu.2023.1088852

5,435 views
11 citations

Perspective

Published on 25 Jan 2023

Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21

in Vaccines and Molecular Therapeutics

Carl R. Alving
Mangala Rao
Gary R. Matyas

Frontiers in Immunology

doi 10.3389/fimmu.2023.1102524

5,514 views
8 citations

Navigation group

Articles

Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study

Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis

Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus

A novel, non-neuronal acetylcholinesterase of schistosome parasites is essential for definitive host infection

Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19

Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines

Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature

Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB

Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

Immunoinformatics design of multivalent epitope vaccine against monkeypox virus and its variants using membrane-bound, enveloped, and extracellular proteins as targets

Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination

Corrigendum: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system

Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21